SYDNEY - Australia's Vitaco is set to enter into a scheme agreement worth more than A$300 million ($228 million ) with Shanghai Pharmaceuticals and Chinese investment firm Primavera Capital.
Under the proposed Vitaco deal, shareholders will receive A$2.25 ($1.71) in cash per share, which values the company at about A$314 million ($238.98 million), the Australian Associated Press reported on Thursday
Vitaco shares were initially offered to investors, when it was listed on the Aussie share market less than a year ago at A$2.10 ($1.60), valuing the company at A$292 million ($222.23 million).
News of the possible merger was favorably received by shareholders as Vitaco shares soared more than 20 percent on Thursday up by 35 cents at A$2.11 ($1.61) at 14:10 AEST.
However, the takeover bid is yet to pass several other conditions including a shareholder and a court approval as well as receiving a green light from Australia's Foreign Investment Review Board.
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263 Registration Number: 130349 
